Abstract: A low strength backfill material having a 28 days compressive strength less than approximately 2.0 MPa is provided. The backfill is suitable for use in areas with dense underground utilities due to its high excavatability and good thermal conductivity. The backfill includes a cementitious binder of approximately 1 weight percent to approximately 10 weight percent and fine aggregates in an amount of approximately 40 to approximately 75 weight percent. Filler is provided at 20 microns to approximately 100 microns for high flowability. A density-controlling agent of 0.0001-5 weight percent is used such that the density of a cured backfill material is approximately 1600 kg/m3 to 2000 kg/m3. Thermally conductive particles having a size range of approximately 0.01 microns to 500 microns in an amount of approximately 0.1 to 10 weight percent are evenly dispersed throughout the backfill.

Abstract: Disclosed herein is a process for chemically synthesizing of hydroquinone derivatives, especially for hydroquinone derivatives with heptadecatrienyl side chain, which is synthesized via a Wittig reaction of 2-(10?-oxononyl)-1,4-diacetoxyl benzene and (3E, 5Z)-3,5-heptadien-1-triphenylphosphonium iodide and then deacetylation. In addition, the product is solid powder.

Abstract: The present disclosure provides a method, an apparatus, and a medium for calculating capacities of a plurality of photovoltaic power stations. The method includes: receiving a plurality of historical weather data sets from the plurality of weather monitoring stations; determining a scene year based on the plurality of historical weather data sets; receiving an actual generating capacity of each photovoltaic power station predicted by a power system dispatch center; extracting weather data of each photovoltaic power station in the scene year from the corresponding historical weather data set; obtaining an available generating capacity of each photovoltaic power station in the scene year based on the weather data; and determining a capacity of each photovoltaic power station in the scene year according to the actual generating capacity and the available generating capacity of each photovoltaic power station.

Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Abstract: Disclosed herein are a method and apparatus for providing and using a broadcast service. Multiple layers of contents may be provided over a broadcast network and a communication network. A terminal may acquire the multiple layers over the broadcast network and the communication network. When a specified layer cannot be acquired over the broadcast network, the terminal may acquire the specified layer over the communication network, using service-layer signaling information provided over the broadcast network. The service-layer signaling information may include information used to acquire the specified layer over the communication network.

Abstract: Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.

Abstract: The present disclosure relates to a method and system for tracking an object of interest in real-time in a multi-camera environment capable of performing data communication without the occurrence of overlapping, and according to the present invention, an object of interest can be tracked in real-time on the basis of mutually captured image data even though capturing zones of a plurality of cameras capable of performing data communication according to the connection therebetween are not overlapped with each other.

Abstract: Provided is a process for converting an alkane to an alkene. The process comprises (a) contacting the alkane and either (i) an oxidizing electrophile comprising a main group element in oxidized form, or (ii) an oxidant and a reduced form of the oxidizing electrophile, in a liquid medium comprising an oxygen acid and optionally one or more additives selected from a non-oxidizable liquid, a salt additive, a Lewis acid, and water, to provide an oxidized intermediate and a reduced form of the oxidizing electrophile; (b) optionally separating the oxidized intermediate and the reduced form of the oxidizing electrophile; and (c) performing an elimination reaction on the oxidized intermediate to provide the alkene and the oxygen acid.

Abstract: A low-jitter digital clock signal generating system which uses optical pulses output from a pulse laser includes a first balanced photodetector that converts first and second optical pulses with a delayed time interval into first and second electrical pulses through first and second photodiodes and outputs first and second modulated pulses generated by allowing the first and second electrical pulses to partially overlap each other, a second balanced photodetector that converts third and fourth optical pulses with the delayed time interval into third and fourth electrical pulses through third and fourth photodiodes, and outputs a second modulated pulse generated by allowing the third and fourth electrical pulses to partially overlap each other, and a capacitor. The capacitor is charged by the first modulated pulse, is discharged by the second modulated pulse, and outputs a voltage according to the charging and discharging as a clock signal.

Abstract: Provided herein are methods of determining whether a subject will respond to a treatment for a neoplasia, neoplastic disorder, tumor, cancer or malignancy, the method comprising detecting the presence or amount of CDS 3 expressing cells in a biological sample from the subject, comparing the measured presence or amount to a reference presence or amount, wherein a modified measured presence or amount as compared to the reference presence or amount is indicative that the subject will or will not respond to the treatment for a neoplasia, neoplastic disorder, tumor, cancer or malignancy. Also described herein are methods of treating a neoplasia, neoplastic disorder, tumor, cancer or malignancy in a subject, the method comprising modulating CDS 3 activity or expression in a myeloid cell, or alternatively, comprising administering a population of CD33hi monocytes or CD33hi macrophages.

Abstract: Provided herein are single wall nanotube constructs to which are convalently linked a plurality of a bifunctional chelator, a therapeutic or a diagnostic radionuclide chelated to each bifunctional chelator and a plurality of morpholino oligonucleotides conjugated to the single wall nanotube. Also provided are single wall nanotube complexes which have the morpholino oligonucleotides on the single wall nanotube constructs hybridized to other morpholino oligonucleotides. The other morpholino oligonucleotides are each conjugated to a therapeutic antibody.

Abstract: Disclosed is a desalination apparatus using a solvent extraction scheme.

Abstract: A solar cell module is provided. The solar cell module includes a first substrate, a second substrate opposite to the first substrate, a cell unit disposed between the first and second substrates, a first thermosetting resin layer disposed between the cell unit and the first substrate, a first thermoplastic resin layer disposed between the cell unit and the first thermosetting resin layer, a second thermosetting resin layer disposed between the cell unit and the second substrate, and a second thermoplastic resin layer disposed between the cell unit and the second thermosetting resin layer, wherein at least one of the first thermoplastic resin layer and the second thermoplastic resin layer contains 0.1% to 10% of light diffusion particles.

Abstract: A cell product for treatment of spinal cord injury, comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. Preferably, the spinal cord injury is complete or incomplete spinal cord injury.

Abstract: The present disclosure provides compounds of any one of Formulae (A) to (L). The present disclosure also provides compositions, uses, and methods that include or involve a compound described herein, a serine/threonine-protein kinase B-Raf (BRAF) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor 1 (VEGFR1) inhibitor, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, or a combination thereof. The compounds, compositions, uses, and methods are useful in changing the pluripotency state of a vertebrate cell to a more nave state.

Abstract: Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.

Abstract: Methods, compositions, and systems for treating subject(s) in need of plasma Factor VIII, particularly a subject having preexisting anti-FVIII inhibitory antibodies, are provided. The methods involve administering to the subject a therapeutically effective amount of an inflammation suppressor, a therapeutically effective amount of a CD8+ T cell depleting agent, and a therapeutically effective amount of a composition comprising a lentiviral vector (LV) comprising an optimized FVIII expression cassette expressibly linked to a megakaryocyte-specific promoter. Such methods, compositions, and systems are useful to treat subjects with blood clotting disorder(s), such as hemophilia A.

Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.

Abstract: A relationship analysis device includes a parameter sample data calculation unit that calculates sample data for parameters for a simulator that receives inputs of data of a first type and outputs data of a second type, calculating sample data; a second type sample data acquisition unit that inputs, to the simulator, observation data and sample data, and obtains sample data of the second type; and a parameter value determination unit that calculates a weight for sample data based on the difference between observation data of the second type and the sample data of the second type, and based on the relationship between a first distribution that the observation data of the first type followed and a second distribution being a distribution of the data of the first type, and calculates a value for the parameters using the calculated weight.